
NMRA Stock Forecast & Price Target
NMRA Analyst Ratings
Bulls say
Neumora Therapeutics is viewed favorably because its post-navacaprant strategy is increasingly centered on a more straightforward, catalyst-rich pipeline, with NMRA-898, NMRA-511, and NMRA-215 each offering differentiated mechanisms and meaningful upcoming updates. The company’s current cash and cash equivalents are expected to fund operations into 3Q27, while the 35% workforce reduction should deliver about $10 million in annualized savings, helping preserve capital through several key readouts. Despite the KOASTAL setback, the combination of a broad seven-program neuroscience pipeline, potential first- or best-in-class assets, and multiple data catalysts over the next 12–18 months supports a constructive long-term outlook.
Bears say
Neumora Therapeutics is facing a severe fundamental setback after discontinuing navacaprant development following KOASTAL-2/3, where it failed both the primary MADRS endpoint and the key SHAPS measure, undermining confidence in its KORA-based strategy. The results were essentially flat versus placebo across studies, with -12.2 vs -12.0 in KOASTAL-2 and -12.1 vs -12.1 after study optimizations in KOASTAL-3, suggesting the mechanism may not be central to treating anhedonia. The company is also cutting 35% of its workforce and expects only $10M in annualized savings, reinforcing the view that it must reset toward a smaller mid-stage biotech profile after losing a major program.
This aggregate rating is based on analysts' research of Neumora Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
NMRA Analyst Forecast & Price Prediction
Start investing in NMRA
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Neumora Therapeutics Inc (NMRA) Forecast
NMRA Analyst Forecast & Price Prediction
Start investing in NMRA
Order type
Buy in
Order amount
Est. shares
0 shares